Eli Lilly Faces Competitive Headwinds as Oral Obesity Drug Orforglipron FDA Decision is Delayed

Eli Lilly is facing increased competitive pressure in the oral GLP-1 market after the FDA delayed the decision date for its candidate, orforglipron, causing LLY shares to fall 2.12% as investors reacted to the shifting competitive landscape.

• The FDA decision date for orforglipron was shifted from March 28 to April 10.
• The setback comes as rival Novo Nordisk's newly launched oral Wegovy pill recorded a strong start, tracking over 18,000 U.S. prescriptions in its first full week.